[go: up one dir, main page]

NO20024815L - Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer - Google Patents

Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer

Info

Publication number
NO20024815L
NO20024815L NO20024815A NO20024815A NO20024815L NO 20024815 L NO20024815 L NO 20024815L NO 20024815 A NO20024815 A NO 20024815A NO 20024815 A NO20024815 A NO 20024815A NO 20024815 L NO20024815 L NO 20024815L
Authority
NO
Norway
Prior art keywords
fungal
treatment
polyene
beta
synthase inhibitor
Prior art date
Application number
NO20024815A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024815D0 (no
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Publication of NO20024815D0 publication Critical patent/NO20024815D0/no
Publication of NO20024815L publication Critical patent/NO20024815L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024815A 2000-04-06 2002-10-04 Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer NO20024815L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
PCT/GB2001/001195 WO2001076627A1 (fr) 2000-04-06 2001-03-20 Traitement des infections fongiques avec des antifongiques a base d'inhibiteur de synthase polyene ou beta glucane combines a des anticorps anti-hsp90

Publications (2)

Publication Number Publication Date
NO20024815D0 NO20024815D0 (no) 2002-10-04
NO20024815L true NO20024815L (no) 2002-12-02

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024815A NO20024815L (no) 2000-04-06 2002-10-04 Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer

Country Status (19)

Country Link
US (4) US20030180285A1 (fr)
EP (4) EP1852128A1 (fr)
JP (1) JP2003530357A (fr)
CN (3) CN101683525A (fr)
AT (1) ATE364396T1 (fr)
AU (2) AU2001240890B2 (fr)
BR (1) BR0109846A (fr)
CA (1) CA2401836A1 (fr)
CY (1) CY1106794T1 (fr)
DE (1) DE60128893T2 (fr)
DK (1) DK1267925T3 (fr)
ES (1) ES2287105T3 (fr)
GB (1) GB0008305D0 (fr)
NO (1) NO20024815L (fr)
NZ (1) NZ520899A (fr)
PL (1) PL358394A1 (fr)
PT (1) PT1267925E (fr)
RU (1) RU2262952C2 (fr)
WO (1) WO2001076627A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
EP1457499A1 (fr) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibiteurs de protéine de choc thermique (HSP90) extracellulaire
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
CN101010100A (zh) 2004-07-02 2007-08-01 纽泰克医药有限公司 癌症的治疗方法
EP1858542A4 (fr) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Compositions et methodes permettant de traiter la permeabilite vasculaire
PT2332909E (pt) * 2005-04-13 2014-12-17 Astex Therapeutics Ltd Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) * 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (fr) * 2007-04-27 2008-11-06 Novartis Ag Composition d'immunoglobulines
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
ES2287105T3 (es) 2007-12-16
AU2001240890B2 (en) 2005-06-16
AU4089001A (en) 2001-10-23
US20080181884A1 (en) 2008-07-31
US20030180285A1 (en) 2003-09-25
EP1267925A1 (fr) 2003-01-02
CN101683525A (zh) 2010-03-31
ATE364396T1 (de) 2007-07-15
US20080193459A1 (en) 2008-08-14
DE60128893D1 (de) 2007-07-26
US20100285029A1 (en) 2010-11-11
NZ520899A (en) 2005-03-24
PT1267925E (pt) 2007-09-04
WO2001076627A8 (fr) 2001-11-15
DE60128893T2 (de) 2007-12-06
WO2001076627A1 (fr) 2001-10-18
BR0109846A (pt) 2003-06-03
EP2011512A1 (fr) 2009-01-07
PL358394A1 (en) 2004-08-09
CA2401836A1 (fr) 2001-10-18
NO20024815D0 (no) 2002-10-04
EP1267925B1 (fr) 2007-06-13
EP1267925B8 (fr) 2007-08-29
EP1852128A1 (fr) 2007-11-07
EP1818062A1 (fr) 2007-08-15
EP1818062A3 (fr) 2007-10-24
CN1420786A (zh) 2003-05-28
JP2003530357A (ja) 2003-10-14
CN101095952A (zh) 2008-01-02
CY1106794T1 (el) 2012-05-23
RU2002129510A (ru) 2004-03-27
RU2262952C2 (ru) 2005-10-27
DK1267925T3 (da) 2007-10-15
GB0008305D0 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
NO20024815L (no) Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer
ECSP20076683A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
AR054474A1 (es) Formulacion de anticuerpos estables
NZ602256A (en) Monoclonal antibodies against the rgm a protein and uses thereof
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
EA201100527A1 (ru) Биологические продукты
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
PE20071055A1 (es) Anticuerpos anti mn
EP1718749A4 (fr) Anticorps monoclonal anti af-20 humanise
CY1109121T1 (el) Θεραπεια μυκητιασικων μολυνσεων
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
WO2022212654A3 (fr) Anticorps monoclonaux à réaction croisée contre les coronavirus
ATE535259T1 (de) Immunogener, monoklonaler antikörper
TH115861A (th) แอนตี้บอดี้ต่ออะไมลอยด์-เบต้า เปปไทด์และวิธีการใช้สิ่งเหล่านี้

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application